Data from a 1,195-patient trial demonstrate that Exelon® Patch (rivastigmine transdermal patch) may be a potential treatment approach for the management of Alzheimer's Disease.
The results of the study, which were presented at the ongoing International Conference on Alzheimer's Disease and Related Disorders (ICAD) in Spain, show that, compared to those on placebo, patients receiving the patch had significant improvements in memory, were better able to maintain everyday activities and could complete a concentration task faster.
Additionally, because of its ease of use, the patch is said to be the preferred method of drug delivery among caregivers involved in the study.
Transdermal patches are designed to provide controlled, continuous delivery of drug through the skin. This maintains steady drug levels in the bloodstream, which may improve tolerability and consequently allow access to higher doses.
In addition, patches may help caregivers to monitor treatment compliance because they provide visual reassurance that the medication has been taken.
Exelon is a cholinesterase inhibitor marketed by Novartis Pharmaceuticals that has also been shown to improve symptoms in Parkinson's Disease dementia.
More details about the clinical study from this press release.
.jpg)
Comment Preview